Live Breaking News & Updates on Generating Exploratory Trials

Expert panel provides guidance for optimized design of early drug trials for Alzheimer s, related dementias
An expert panel convened by the Alzheimer s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) provides guidance on best practices for the design of early drug trials for Alzheimer s disease, frontotemporal degeneration (FTD), and other neurodegenerative dementias. Their guidance was published in the May 18, 2021 issue of
Neurology®, the medical journal of the American Academy of Neurology ( Value-Generating Exploratory Trials in Neurodegenerative Dementias ).
These efficiencies in clinical trials can help to achieve proof of concept more rapidly and at lower costs. The estimated cost of developing an Alzheimer s drug is eight times more than a cancer drug and takes nearly twice as long to develop. The panel, which comprised clinicians, researchers, and statisticians from academia, biotech, and pharmaceutical companies, ....

United States , Susan Lj Dickinson , Howard Fillit , Emily Henderson , Association For Frontotemporal Degeneration , American Academy Of Neurology Value , Alzheimer Drug Discovery Foundation , Drug Discovery Foundation , Frontotemporal Degeneration , American Academy , Generating Exploratory Trials , Founding Executive Director , Chief Science Officer , Drug Discovery , Alzheimer 39s Disease , Drug Discovery , Frontotemporal Degeneration , ஒன்றுபட்டது மாநிலங்களில் , சூசன் ல்ஜ் டிக்கின்சன் , எமிலி ஹென்டர்சன் , முதுமறதி மருந்து கண்டுபிடிப்பு அடித்தளம் , மருந்து கண்டுபிடிப்பு அடித்தளம் , அமெரிக்கன் கலைக்கழகம் , ஸ்தாபகம் நிர்வாகி இயக்குனர் , தலைமை அறிவியல் அதிகாரி , மருந்து கண்டுபிடிப்பு ,